137 related articles for article (PubMed ID: 34800625)
1. Association of cannabinoid receptor modulation with normal and abnormal skeletal remodelling: A systematic review and meta-analysis of in vitro, in vivo and human studies.
Sophocleous A; Yiallourides M; Zeng F; Pantelas P; Stylianou E; Li B; Carrasco G; Idris AI
Pharmacol Res; 2022 Jan; 175():105928. PubMed ID: 34800625
[TBL] [Abstract][Full Text] [Related]
2. Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation.
Zeng F; Wade A; Harbert K; Patel S; Holley JS; Dehghanpuor CK; Hopwood T; Marino S; Sophocleous A; Idris AI
Sci Rep; 2024 Mar; 14(1):5782. PubMed ID: 38461339
[TBL] [Abstract][Full Text] [Related]
3. Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade.
Crespillo A; Suárez J; Bermúdez-Silva FJ; Rivera P; Vida M; Alonso M; Palomino A; Lucena MA; Serrano A; Pérez-Martín M; Macias M; Fernández-Llébrez P; Rodríguez de Fonseca F
Biochem J; 2011 Jan; 433(1):175-85. PubMed ID: 20955176
[TBL] [Abstract][Full Text] [Related]
4. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor.
Idris AI; Sophocleous A; Landao-Bassonga E; van't Hof RJ; Ralston SH
Endocrinology; 2008 Nov; 149(11):5619-26. PubMed ID: 18635663
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid CB
Weresa J; Pędzińska-Betiuk A; Kossakowski R; Malinowska B
Pharmacol Rep; 2019 Feb; 71(1):82-89. PubMed ID: 30500553
[TBL] [Abstract][Full Text] [Related]
6. Bone Cell-autonomous Contribution of Type 2 Cannabinoid Receptor to Breast Cancer-induced Osteolysis.
Sophocleous A; Marino S; Logan JG; Mollat P; Ralston SH; Idris AI
J Biol Chem; 2015 Sep; 290(36):22049-60. PubMed ID: 26195631
[TBL] [Abstract][Full Text] [Related]
7. Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells.
Jiang S; Fu Y; Williams J; Wood J; Pandarinathan L; Avraham S; Makriyannis A; Avraham S; Avraham HK
PLoS One; 2007 Jul; 2(7):e641. PubMed ID: 17653268
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative.
Silva NR; Gomes FV; Fonseca MD; Mechoulam R; Breuer A; Cunha TM; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):369-377. PubMed ID: 28720466
[TBL] [Abstract][Full Text] [Related]
9. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.
Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB
Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of salivary secretion by activation of cannabinoid receptors.
Prestifilippo JP; Fernández-Solari J; de la Cal C; Iribarne M; Suburo AM; Rettori V; McCann SM; Elverdin JC
Exp Biol Med (Maywood); 2006 Sep; 231(8):1421-9. PubMed ID: 16946411
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid CB
Olianas MC; Dedoni S; Onali P
Life Sci; 2021 Jul; 276():119407. PubMed ID: 33794254
[TBL] [Abstract][Full Text] [Related]
12. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Sep; 56(3):185-92. PubMed ID: 17656103
[TBL] [Abstract][Full Text] [Related]
13. Peripheral cannabinoid receptor, CB2, regulates bone mass.
Ofek O; Karsak M; Leclerc N; Fogel M; Frenkel B; Wright K; Tam J; Attar-Namdar M; Kram V; Shohami E; Mechoulam R; Zimmer A; Bab I
Proc Natl Acad Sci U S A; 2006 Jan; 103(3):696-701. PubMed ID: 16407142
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol disrupts the consolidation of specific and generalized fear memories via dorsal hippocampus CB
Stern CAJ; da Silva TR; Raymundi AM; de Souza CP; Hiroaki-Sato VA; Kato L; Guimarães FS; Andreatini R; Takahashi RN; Bertoglio LJ
Neuropharmacology; 2017 Oct; 125():220-230. PubMed ID: 28754373
[TBL] [Abstract][Full Text] [Related]
15. Ligands of the CB2 cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in mice.
Poleszak E; Wośko S; Sławińska K; Wyska E; Szopa A; Sobczyński J; Wróbel A; Doboszewska U; Wlaź P; Wlaź A; Szponar J; Skałecki P; Serefko A
Behav Brain Res; 2020 Jan; 378():112297. PubMed ID: 31626848
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid CB
Spiller KJ; Bi GH; He Y; Galaj E; Gardner EL; Xi ZX
Br J Pharmacol; 2019 May; 176(9):1268-1281. PubMed ID: 30767215
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological actions of cannabinoids.
Pertwee RG
Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI.
Chin CL; Tovcimak AE; Hradil VP; Seifert TR; Hollingsworth PR; Chandran P; Zhu CZ; Gauvin D; Pai M; Wetter J; Hsieh GC; Honore P; Frost JM; Dart MJ; Meyer MD; Yao BB; Cox BF; Fox GB
Br J Pharmacol; 2008 Jan; 153(2):367-79. PubMed ID: 17965748
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
20. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
McPartland JM; Duncan M; Di Marzo V; Pertwee RG
Br J Pharmacol; 2015 Feb; 172(3):737-53. PubMed ID: 25257544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
